FOXP3+ regulatory T cells as biomarkers in human malignancies

Expert Opinion on Biological Therapy

Volumn 8, Issue 12, 2008, Pages 1897-1920

  Bignone, Paola A ^a   Banham, Alison H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Biomarker; Cancer; Forkhead box P3; FOXP3; Tumour immunity; Tumour infiltrating lymphocytes

Indexed keywords

MESSENGER RNA; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER;

CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL LINEAGE; CLINICAL PRACTICE; DIAGNOSTIC VALUE; DISEASE COURSE; DNA BINDING; FRAMESHIFT MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MICE; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

EID: 57649152965     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802494022     Document Type: Review

References (143)

1. + regulatory T cells: Current controversies and future perspectives. Eur J Immunol 2006; 36:2832-6
2. Beyer M, Schultze JL. Immunoregulatory T cells: role and potential as a target in malignancy. Curr Oncol Rep 2008;10:130-6
3. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008;20:241-6
4. Gallimore AM, Godkin AJ. Regulatory T cells and tumour immunity - observations in mice and men. Immunology 2008;123:157-63
5. Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008;38:925-7
6. Bates GJ, Bignone PA, Banham AH. In Reply. J Clin Oncol 2007;25:4500-1
7. Yamamoto M, Tsuji-Takayama K, Suzuki M, et al. Comprehensive analysis of FOXP3 mRNA expression in leukemia and transformed cell lines. Leuk Res 2008;32:651-8
8. Kretschmer K, Apostolou I, Jaeckel E, et al. Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol Rev 2006;212:163-9
9. -thymocytes express FOXP3 in the absence of a TCR. J Immunol 2008;180:3651-4
10. + regulatory T cells rescue scurfy mice. Eur J Immunol 2008;38:1814-21
11. + conventional T cells. Eur J Immunol 2007;37:2378-89
12. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007;5:e38 published online 30 January 2007 doi:10.1371/journal.pbio.0050038
13. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-8
14. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8:523-32
15. Wang B, Lin D, Li C, et al. Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. J Biol Chem 2003;278:24259-68
16. Chatila TA, Blaeser F, Ho N, et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000;106:R75-81
17. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-1
18. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/ winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001;27:68-73
19. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20
20. van der Vliet HJ, Nieuwenhuis EE. IPEX as a result of mutations in FOXP3. Clin Dev Immunol 2007;2007:89017
21. + regulatory T cells. Nat Immunol 2003;4:330-6
22. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61
23. + T regulatory cells. Nat Immunol 2003; 4:337-42
24. Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22:329-41
25. high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53
26. Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007;19:345-54
27. + regulatory T cells at the single-cell level. Eur J Immunol 2005;35:1681-91
28. - T cells by T cell receptor stimulation is TGF-β-dependent but does not confer a regulatory phenotype. Blood 2007;110:2983-90
29. - cells. Proc Natl Acad Sci USA 2005; 102:4103-8
30. - T cells. J Clin Invest 2003;112:1437-43
31. + T cells. Eur J Immunol 2007;37:129-38
32. + T reg cells. J Exp Med 2006;203:1701-11
33. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-700
34. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61
35. Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8
36. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307
37. + regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Invest Drugs 2007; 8:1002-8
38. Zuo T, Wang L, Morrison C, et al. FOXP3 Is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007;129:1275-86
39. Ebert LM, Tan BS, Browning J, et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 2008;68:3001-9
40. Hinz S, Pagerols-Raluy L, Oberg HH, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007;67:8344-50
41. Karanikas V, Speletas M, Zamanakou M, et al. Foxp3 expression in human cancer cells. J Transl Med 2008;6:19 published online 22 April 2008, doi:10.1186/1479-5876-6-19
42. + regulatory T cells. Int Immunol 2004;16:1643-56
43. + T-cell activation. Immunology 2006;119:203-11
44. -cells. Eur J Immunol 2008; 38:1381-90
45. + Tregs. J Clin Invest 2005; 115:3276-84
46. Banham AH, Brown PJ, Lyne L, et al. Is FOXP3 expressed in cutaneous T-cell lymphomas? Eur J Haematol 2008;80:90-1
47. + regulatory T cells at the single-cell level. Eur J Immunol 2006;36:245-6; author reply 6
48. Du J, Huang C, Zhou B, et al. Isoform-specific inhibition of RORα-mediated transcriptional activation by human FOXP3. J Immunol 2008;180:4785-92
49. Fox BC, Bignone PA, Brown PJ, et al. Defense of the clone: antibody 259D effectively labels human FOXP3 in a variety of applications. Blood 2008;111:3897-9
50. Tran DQ, Shevach EM. Response: Anti human FOXP3 mAb PCH101 stains activated human naive T cells nonspecifically. Blood 2008;111:464-6
51. Pillai V, Karandikar NJ. Attack on the clones? Human FOXP3 detection by PCH101, 236A/E7, 206D, and 259D reveals 259D as the outlier with lower sensitivity. Blood 2008;111:463-4
52. Chang X, Gao JX, Jiang Q, et al. The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J Exp Med 2005;202:1141-51
53. Zuo T, Liu RCD, Zhang H, et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 2007;117:3765-73
54. Chen G, Chen C, Wang L, et al. Cutting Edge: Broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3- expressing cells. J Immunol 2008;180:5163-6
55. Liston A, Farr AG, Chen Z, et al. Lack of Foxp3 function and expression in the thymic epithelium. J Exp Med 2007;204:475-80
56. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-80
57. + regulatory T cells, in adult T-cell leukaemia/ lymphoma cells. Br J Haematol 2004;126:81-4
58. Roncador G, Garcia JF, Maestre L, et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 2005;19:2247-53
59. Klemke CD, Fritzsching B, Franz B, et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006;20:1123-9
60. Hallermann C, Niermann C, Schulze HJ. Regulatory T-cell phenotype in association with large cell transformation of mycosis fungoides. Eur J Haematol 2007;78:260-3
61. Kasprzycka M, Marzec M, Liu X, et al. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci USA 2006;103:9964-9
62. Wolke C, Tadje J, Bukowska A, et al. Assigning the phenotype of a natural regulatory T-cell to the human T-cell line, KARPAS-299. Int J Mol Med 2006;17:275-8
63. Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations. Eur J Haematol 2008;80:483-9
64. + regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007;21:2512-8
65. Karube K, Aoki R, Sugita Y, et al. The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/ lymphoma. Mod Pathol 2008;21:617-25
66. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9
67. Wolf AM, Rumpold H, Wolf D, et al. Role of forkhead box protein 3 expression in invasive breast cancer. J Clin Oncol 2007;25:4499-500; author reply 500-1
68. Gupta S, Joshi K, Wig JD, et al. Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta oncologica 2007;46:792-7
69. Ghebeh H, Barhoush E, Tulbah A, et al. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 2008;8:57. published online 23 February 2008, doi:10.1186/1471-2407-8-57
70. + regulatory T cells. Clin Cancer Res 2008;14:2413-20
71. Alvaro T, Lejeune M, Salvadó MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467-73
72. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957-64
73. + cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052-9
74. + T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126:2217-23
75. + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193-200
76. + regulatory T cells. J Immunol 2005;175:4180-3
77. + T cells selectively kill B lymphocytes. Blood 2006;107:3925-32
78. Kelley T, Beck R, Absi A, et al. Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma 2007;48:2403-11
79. Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008;127:280-5
80. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007;13:1299-307
81. Wang R, Wan Q, Kozhaya L, et al. Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. PLoS One 2008;3:e2705. published online 16 July 2008, doi:10.1371/journal.pone.0002705
82. Ollendorff V, Noguchi T, deLapeyriere O, et al. The GARP gene encodes a new member of the family of leucine-rich repeat-containing proteins. Cell Growth Differ 1994;5:213-9
83. Su AI, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004;101:6062-7. http://symatlas.gnf.org/SymAtlas/
84. Schultz J, Milpetz F, Bork P, et al. SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci USA 1998;95:5857-64. http://smart.embl-heidelberg.de/
85. Hubbard TJ, Aken BL, Beal K, et al. Ensembl 2007. Nucleic Acids Res 2007;35:D610-7. http://www.ensembl.org/[Ensembl release 50 - Jul 2008]
86. Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol 2003;3:189-98
87. + regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 2004;200:1123-34
88. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005;116:961-8; quiz 9
89. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002;99:3493-9
90. + T lymphocytes from MHC class II-deficient mice exhibit regulatory activity. J Immunol 2005;175:246-53
91. + regulatory thymocytes. Blood 2003;102:4107-14
92. + regulatory T cells in human ovarian carcinoma. Cancer Res 2005;65:5020-6
93. + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12:5423-34
94. Biocompare. Buyer's Guide For Life Scientists. http://www.biocompare.com/
95. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465-72
96. + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005; 92:913-20
97. Albers AE, Ferris RL, Kim GG, et al. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 2005;54:1072-81
98. Bose A, Chakraborty T, Chakraborty K, et al. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 2008;8:10. Published online 12 June 2008 http://www.cancerimmunity.org/v8p10/080511.htm [Last accessed 27 September 2008]
99. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-39
100. + regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007;13:902-11
101. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-93
102. + regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 2008;34:173-9
103. + T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 2006;33:386-90
104. + regulatory T cells in human colorectal cancer. J Transl Med 2006;4:52. published online 13 December 2006, doi:10.1186/ 1479-5876-4-52
105. Ling KL, Pratap SE, Bates GJ, et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 2007;7:7, published online 28 March 2007. Available from: http://www.cancerimmunity.org/v7p7/ 070206.htm [Last accessed 27 September 2008]
106. + regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 2006;1:e129 published online 27 December 2006, doi:10.1371/ journal. pone.0000129
107. Grabenbauer GG, Lahmer G, Distel L, et al. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006;12:3355-60
108. Hillen F, Baeten CI, van de Winkel A, et al. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother 2008;57:97-106
109. De Panfilis G, Campanini N, Santini M, et al. Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma. J Invest Dermatol 2008;128:676-84
110. + T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother 2008;57(12):1795-805
111. Hussain SF, Yang D, Suki D, et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neurooncol 2006;8:261-79
112. + T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 2007;83:145-52
113. high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-405
114. Fox SB, Bates GJ, Han C, et al. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2α but not HIF-1α. Prostate 2007;67:623-9
115. + regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14:1032-40
116. Loskog AS, Ninalga C, Paul-Wetterberg G, et al. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol 2007;177:353-8
117. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-43
118. Shah CA, Allison KH, Garcia RL, et al. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: Association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol 2008;109:215-9
119. + lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol 2008; 110:216-21
120. +/regulatory T-cell ratio: Which variable determines survival of cervical cancer patients? Clin Cancer Res 2008;14:2028-35
121. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56:1743-53
122. high regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer 2007;96:617-22
123. - T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006;67:1-12
124. + regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866-72
125. Anraku M, Cunningham KS, Yun Z, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2008;135:823-9
126. + regulatory T cells in gastric cancer. Int J Cancer 2008;122:2286-93
127. + regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 2008;98:148-53
128. Perrone G, Ruffini PA, Catalano V, et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008;44(13):1875-82
129. Yoshioka T, Miyamoto M, Cho Y, et al. Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer 2008;98:1258-63
130. + regulatory T cells in oral squamous cell carcinomas detected by chromogenic immunohistochemical double staining. J Oral Pathol Med 2008;37(8):485-9
131. + regulatory T cells in patients with multiple myeloma. Blood 2006;107:3940-9
132. Kohno T, Yamada Y, Akamatsu N, et al. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci 2005;96:527-33
133. Yano H, Ishida T, Inagaki A, et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 2007;120:2052-7
134. + T cells. Cancer Sci 2008;99:98-106
135. Capriotti E, Vonderheid EC, Thoburn CJ, et al. Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma 2008;49:1190-201
136. + cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007;128:958-65
137. Lee NR, Song EK, Jang KY, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leak Lymphoma 2008;49:247-56
138. Alvaro T, Lejeune M, Salvadó MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350-7
139. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390-8
140. + regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007;110:847-50
141. + T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107:3639-46
142. + regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006;66:10145-52
143. + regulatory T cell population by non-Hodgkin's lymphoma. Blood 2008;111:5359-70